Search

Your search keyword '"Nonomura, Norio"' showing total 1,385 results
Start Over Author "Nonomura, Norio" Language english
1,385 results on '"Nonomura, Norio"'

1. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

Author

Yoshimura, Akihiro, Kato, Taigo, Nakai, Yasutomo, Tsujihata, Masao, Toyoda, Shingo, Sato, Mototaka, Matsuzaki, Kyosuke, Nakata, Wataru, Takao, Tetsuya, Inoguchi, Syunsuke, Okuda, Yohei, Yamamichi, Gaku, Ishizuya, Yu, Yamamoto, Yoshiyuki, Hatano, Koji, Kawashima, Atsunari, Takada, Shingo, Inoue, Hitoshi, Nishimura, Kensaku, Miyake, Osamu, Fujita, Kazutoshi, Nakayama, Masashi, Nishimura, Kazuo, and Nonomura, Norio

Published
2024
Full Text
View/download PDF

16. Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients

Author

Jingushi, Kentaro, Kawashima, Atsunari, Saito, Takuro, Kanazawa, Takayuki, Motooka, Daisuke, Kimura, Tomonori, Mita, Masashi, Yamamoto, Akinaru, Uemura, Toshihiro, Yamamichi, Gaku, Okada, Koichi, Tomiyama, Eisuke, Koh, Yoko, Matsushita, Makoto, Kato, Taigo, Hatano, Koji, Uemura, Motohide, Tsujikawa, Kazutake, Wada, Hisashi, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

19. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer

Author

Tomiyama, Eisuke, Fujita, Kazutoshi, Matsuzaki, Kyosuke, Narumi, Ryohei, Yamamoto, Akinaru, Uemura, Toshihiro, Yamamichi, Gaku, Koh, Yoko, Matsushita, Makoto, Hayashi, Yujiro, Hashimoto, Mamoru, Banno, Eri, Kato, Taigo, Hatano, Koji, Kawashima, Atsunari, Uemura, Motohide, Ukekawa, Ryo, Takao, Tetsuya, Takada, Shingo, Uemura, Hirotsugu, Adachi, Jun, Tomonaga, Takeshi, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

21. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study

Author

Kato, Taigo, Fujita, Kazutoshi, Minami, Takafumi, Nagahara, Akira, Hyashi, Yujiro, Nakata, Wataru, Matsuzaki, Kyosuke, Nakano, Kosuke, Hatano, Koji, Kawashima, Atsunari, Imamura, Ryoichi, Takada, Shingo, Nishimura, Kensaku, Tsujihata, Masao, Takao, Tetsuya, Nakai, Yasutomo, Nakayama, Masashi, Nishimura, Kazuo, Uemura, Motohide, Uemura, Hirotsugu, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

28. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation

Author

Kato, Taigo, Matsubara, Nobuaki, Shiota, Masaki, Eto, Masatoshi, Osawa, Takahiro, Abe, Takashige, Shinohara, Nobuo, Yasumizu, Yota, Tanaka, Nobuyuki, Oya, Mototsugu, Nishimoto, Koshiro, Hayashi, Takuji, Nakayama, Masashi, Kojima, Takahiro, Namikawa, Kenjiro, Fujisawa, Takao, Okano, Susumu, Hida, Eisuke, Nakamura, Yoshiaki, Bando, Hideaki, Yoshino, Takayuki, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

30. Japanese clinical practice guidelines for prostate cancer 2023.

Author

Kohjimoto, Yasuo, Uemura, Hiroji, Yoshida, Masahiro, Hinotsu, Shiro, Takahashi, Satoru, Takeuchi, Tsutomu, Suzuki, Kazuhiro, Shinmoto, Hiroshi, Tamada, Tsutomu, Inoue, Takahiro, Sugimoto, Mikio, Takenaka, Atsushi, Habuchi, Tomonori, Ishikawa, Hitoshi, Mizowaki, Takashi, Saito, Shiro, Miyake, Hideaki, Matsubara, Nobuaki, Nonomura, Norio, and Sakai, Hideki

Subjects
MEDICAL quality control, PROSTATE cancer patients, PROSTATE cancer, ONCOLOGY, TEXTBOOKS
Abstract

This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under the leadership of the Japanese Urological Association, with members selected from multiple academic societies and related organizations (Japan Radiological Society, Japanese Society for Radiation Oncology, the Department of EBM and guidelines, Japan Council for Quality Health Care (Minds), Japanese Society of Pathology, and the patient group (NPO Prostate Cancer Patients Association)), in accordance with the Minds Manual for Guideline Development (2020 ver. 3.0). The most important feature of this revision is the adoption of systematic reviews (SRs) in determining recommendations for 14 clinical questions (CQs). Qualitative SRs for these questions were conducted, and the final recommendations were made based on the results through the votes of 24 members of the guideline development group. Five algorithms based on these results were also created. Contents not covered by the SRs, which are considered textbook material, have been described in the general statement. In the general statement, a literature search for 14 areas was conducted; then, based on the general statement and CQs of the Japanese Clinical Practice Guidelines for Prostate Cancer 2016, the findings revealed after the 2016 guidelines were mainly described. This article provides an overview of these guidelines. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference—JAPAN 2023.

Author

Hashimoto, Kohei, Kosaka, Takeo, Terada, Naoki, Kimura, Takahiro, Nonomura, Norio, Suzuki, Hiroyoshi, and Uemura, Hiroji

Subjects
UROLOGISTS, PHYSICIANS, PROSTATE cancer, VOTING, MEDICAL care
Abstract

Objective: To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Methods: Among the 198 questions discussed at the APCCC 2022, the APCCC‐JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high‐level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on‐site using a web‐based system. The results were compared with those of APCCC 2022. Results: This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment. Conclusions: APCCC‐JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context‐specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision‐making in the management of advanced prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study

Author

Kato, Taigo, Nagahara, Akira, Kawamura, Norihiko, Nakata, Wataru, Soda, Tetsuji, Matsuzaki, Kyosuke, Hatano, Koji, Kawashima, Atsunari, Ujike, Takeshi, Imamura, Ryoichi, Nishimura, Kensaku, Takada, Shingo, Tsujihata, Masao, Yamaguchi, Seiji, Takao, Tetsuya, Nishimura, Kazuo, Nonomura, Norio, and Uemura, Motohide

Published
2021
Full Text
View/download PDF

36. Cutibacterium acnes‐derived extracellular vesicles promote tumor growth in renal cell carcinoma.

Author

Jingushi, Kentaro, Kawashima, Atsunari, Tanikawa, Sayaka, Saito, Takuro, Yamamoto, Akinaru, Uemura, Toshihiro, Sassi, Nesrine, Ishizuya, Yu, Yamamoto, Yoshiyuki, Kato, Taigo, Hatano, Koji, Hase, Hiroaki, Nonomura, Norio, and Tsujikawa, Kazutake

Abstract

Bacterial flora are present in various parts of the human body, including the intestine, and are thought to be involved in the etiology of various diseases such as multiple sclerosis, intestinal diseases, cancer, and uterine diseases. In recent years, the presence of bacterial 16S rRNA genes has been revealed in blood, which was previously thought to be a sterile environment, and characteristic blood microbiomes have been detected in various diseases. However, the mechanism and the origin of the bacterial information are unknown. In this study, we performed 16S rRNA metagenomic analysis of bacterial DNA in serum extracellular vesicles from five healthy donors and seven patients with renal cell carcinoma and detected Cutibacterium acnes DNA as a characteristic bacterial DNA in the serum extracellular vesicles of patients with renal cell carcinoma. In addition, C. acnes DNA was significantly reduced in postoperative serum extracellular vesicles from patients with renal cell carcinoma compared with that in preoperative serum extracellular vesicles from these patients and was also detected in tumor tissue and extracellular vesicles from tumor tissue‐associated microbiota, suggesting an association between C. acnes extracellular vesicles and renal cell carcinoma. C. acnes extracellular vesicles were taken up by renal carcinoma cells to enhance their proliferative potential. C. acnes extracellular vesicles also exhibited tumor‐promoting activity in a mouse model of renal cancer allografts with enhanced angiogenesis. These results suggest that extracellular vesicles released by C. acnes localized in renal cell carcinoma tissues act in a tumor‐promoting manner. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

Author

Kawashima, Atsunari, Yamamoto, Yoshiyuki, Sato, Mototaka, Nakata, Wataru, Kakuta, Yoichi, Ishizuya, Yu, Yamaguchi, Yuichiro, Yamamoto, Akinaru, Yoshida, Takahiro, Takayama, Hitoshi, Takada, Tsuyoshi, Inoue, Hitoshi, Okuda, Yohei, Kato, Taigo, Hatano, Koji, Uemura, Motohide, Nonomura, Norio, and Imamura, Ryoichi

Published
2021
Full Text
View/download PDF

43. Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma

Author

Yamamoto, Akinaru, Kawashima, Atsunari, Sakai, Shinsuke, Mita, Masashi, Sassi, Nesrine, Inoguchi, Shunsuke, Horibe, Yuki, Yoshimura, Akihiro, Tani, Masaru, Yutong, Liu, Okuda, Yohei, Oka, Toshiki, Uemura, Toshihiro, Yamamichi, Gaku, Ishizuya, Yu, Hayashi, Takuji, Yamamoto, Yoshiyuki, Kato, Taigo, Hatano, Koji, Kakuta, Yoichi, Imamura, Ryoichi, Takahara, Shiro, Kimura, Tomonori, and Nonomura, Norio

Published
2024
Full Text
View/download PDF

46. Downregulation of TCF7 and LEF1 is a key determinant of tumor-infiltrating regulatory T-cell function.

Author

Kidani, Yujiro, Kitagawa, Yohko, Hagiwara, Masaki, Kawashima, Atsunari, Kanazawa, Takayuki, Wada, Hisashi, Uemura, Motohide, Nonomura, Norio, Motooka, Daisuke, Nakamura, Shota, Ohkura, Naganari, and Sakaguchi, Shimon

Subjects
REGULATORY T cells, FORKHEAD transcription factors, T cells, CELL analysis, GENETIC transcription regulation, DOWNREGULATION
Abstract

Forkhead box P3 (Foxp3)-expressing regulatory T (Treg) cells play essential roles in immune homeostasis but also contribute to establish a favorable environment for tumor growth by suppressing anti-tumor immune responses. It is thus necessary to specifically target tumor-infiltrating Treg cells to minimize effects on immune homeostasis in cancer immunotherapy. However, molecular features that distinguish tumor-infiltrating Treg cells from those in secondary lymphoid organs remain unknown. Here we characterize distinct features of tumor-infiltrating Treg cells by global analyses of the transcriptome and chromatin landscape. They exhibited activated phenotypes with enhanced Foxp3-dependent transcriptional regulation, yet being distinct from activated Treg cells in secondary lymphoid organs. Such differences may be attributed to the extensive clonal expansion of tumor-infiltrating Treg cells. Moreover, we found that TCF7 and LEF1 were specifically downregulated in tumor-infiltrating Treg cells both in mice and humans. These factors and Foxp3 co-occupied Treg suppressive function-related gene loci in secondary lymphoid organ Treg cells, whereas the absence of TCF7 and LEF1 accompanied altered gene expression and chromatin status at these gene loci in tumor-infiltrating Treg cells. Functionally, overexpression of TCF7 and LEF1 in Treg cells inhibited the enhancement of Treg suppressive function upon activation. Our results thus show the downregulation of TCF7 and LEF1 as markers of highly suppressive Treg cells in tumors and suggest that their absence controls the augmentation of Treg suppressive function in tumors. These molecules may be potential targets for novel cancer immunotherapy with minimum effects on immune homeostasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.

Author

Mori, Kazuyuki, Hatakeyama, Shingo, Enokida, Hideki, Miyake, Hideaki, Kikuchi, Eiji, Nishiyama, Hiroyuki, Ichikawa, Tomohiko, Kamai, Takao, Kaji, Yasushi, Kume, Haruki, Kondo, Tsunenori, Matsuyama, Hideyasu, Masumori, Naoya, Kawauchi, Akihiro, Takenaka, Atsushi, Uemura, Hirotsugu, Eto, Masatoshi, Nonomura, Norio, Fujii, Yasuhisa, and Hinotsu, Shiro

Subjects
TRANSITIONAL cell carcinoma, EVIDENCE-based management, MEDICAL personnel
Abstract

This article is an English translation of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma (2nd edition) published in June 2023. The Japanese Urological Association's (JUA) Guidelines Committee on Upper Tract Urothelial Carcinoma (UTUC) created a 2023 update guideline to support clinicians' current evidence‐based management of UTUC and to incorporate its recommendations into clinical practice. The new guideline adhered as closely as possible to the Minds Manual for Guideline Development 2020 ver. 3.0. Findings related to epidemiological, pathological, diagnosis, treatment, and follow‐up were reviewed. In addition, seven clinical questions (CQs) were set to determine the grade of recommendation and level of evidence. Preconceptions and biases were removed from the preparation process, the overall evidence was evaluated appropriately, and recommendations were made after fully considering the balance between benefits and harms. Although the evidence is still insufficient to be taken up as a CQ, the latest important information is described in seven columns, and clinical issues that should be resolved in the future related to the CQ are described as recommendations for tomorrow. We hope that these guidelines will help medical professionals, patients, and their families involved in the treatment of UTUC in their decision‐making, and hope that a critical review of these guidelines will lead to further refinements in the next edition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Association between nocturnal polyuria and 24‐h blood pressure fluctuations in males with lower urinary tract symptoms: A multicenter prospective study.

Author

Kato, Yoichiro, Akaihata, Hidenori, Takezawa, Kentaro, Maekawa, Shigekatsu, Matsuoka, Kanako, Fukuhara, Shinichiro, Kato, Renpei, Kojima, Yoshiyuki, Nonomura, Norio, and Obara, Wataru

Subjects
POLYURIA, NOCTURIA, BLOOD pressure, URINARY organs, DIASTOLIC blood pressure, SYSTOLIC blood pressure
Abstract

Objectives: Nocturnal polyuria (NP) is one of the causes of nocturia that impairs quality of life. It is necessary to consider that NP is latent when the initial treatment for nocturia is unsatisfactory. Therefore, it is important to establish a treatment for NP based on the pathophysiology. We have previously reported the relationship between NP and fluctuation in blood pressure. The present study aimed to investigate the association between NP and 24‐h blood pressure fluctuations in a multicenter prospective study. Methods: This study included male patients with lower urinary tract symptoms. We categorized the patients into the nonnocturnal polyuria (non‐NP) group (≤0.33) and the NP group (>0.33) based on the nocturnal polyuria index from the frequency volume chart. We measured the 24‐h diurnal blood pressure and compared the two groups. Results: Among 90 patients, 46 in the non‐NP group and 44 in the NP group were included. There was no significant difference in the systolic and diastolic blood pressure during waking time between the two groups; however, the degree of systolic blood pressure reduction during sleep time in the NP group was significantly less than that in the non‐NP group (p = 0.039). In the multivariate analysis, systolic BP during sleep was significantly associated with NP (OR 0.970, p = 0.028). Conclusion: NP is associated with inadequate nocturnal blood pressure reduction in males, suggesting that reduction in nocturnal blood pressure may lead to improvement in nocturia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.

Author

Tomiyama, Eisuke, Fujita, Kazutoshi, Hashimoto, Mamoru, Uemura, Hirotsugu, and Nonomura, Norio

Subjects
BLADDER cancer, CANCER diagnosis, BLADDER, TUMOR markers, CANCER relapse, BIOMARKERS
Abstract

Bladder cancer is a common urological cancer with a high recurrence rate that requires long‐term follow‐up, and early detection positively affects prognosis. To date, the initial diagnosis and follow‐up for bladder cancer rely on cystoscopy, which is an invasive and expensive procedure. Therefore, urinary markers for the detection of bladder cancer have attracted research attention for decades to reduce unnecessary cystoscopies. Urine, which is in continuous contact with bladder cancer, is considered a suitable fluid for providing tumor information. Urinary cytology is the only widely used urinary marker in clinical practice; however, it has poor sensitivity for low‐grade tumors; indicating the need for novel urinary markers. Considerable research has been conducted on this topic over the years, resulting in a complex landscape with a wide range of urinary markers, including protein‐, exfoliated cell‐, RNA‐, DNA‐, and extracellular vesicle‐based markers. Although some of these markers have been approved by the U.S. Food and Drug Administration and are commercially available, their use in clinical practice is limited. To facilitate clinical application, potential urinary markers must withstand prospective clinical trials and be easy for patients and clinicians to understand and utilize in a clinical context. This review provides a comprehensive overview of currently available and recently reported promising urinary markers for bladder cancer. Additionally, the challenges and the prospects of these urinary markers for clinical implementation in bladder cancer treatment were discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results